Compare Dolby Laboratories, Inc. (DLB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Illumina, Inc. — how do they compare? Dolby Laboratories, Inc. trades at $58.65 (market cap $5.47B), while Illumina, Inc. trades at $270.58 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 7.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Illumina, Inc. for 83 Days on average.
| DLB | ILMN | |
|---|---|---|
Market Cap | $5.47B | $39.95B |
Volume | 1,058,284 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $70.09 | $293.69 |
52-Week Low | $48.51 | $91.00 |
Typical Hold Time | 98 Days | 83 Days |
Enterprise Value | $4.85B | $41.31B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
